# Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients.

Study · id `cardio:ct-nct03088670` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03088670](<https://clinicaltrials.gov/study/NCT03088670>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03088670

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 299 participants.

## Technical summary

Registry record NCT03088670. Randomized; no masking; primary purpose treatment. Start 2013-04-23 (actual); primary completion 2014-03-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 299 participants (enrolled count; ClinicalTrials.gov record NCT03088670, source copy `cardio:ctgov-nct03088670-2017-03-23`, retrieved 2026-10-26)
- Started: 2013-04-23 (actual) (ClinicalTrials.gov record NCT03088670, source copy `cardio:ctgov-nct03088670-2017-03-23`, retrieved 2026-10-26)
- Primary completion: 2014-03-30 (actual) (ClinicalTrials.gov record NCT03088670, source copy `cardio:ctgov-nct03088670-2017-03-23`, retrieved 2026-10-26)
- Completion: 2014-10-03 (actual) (ClinicalTrials.gov record NCT03088670, source copy `cardio:ctgov-nct03088670-2017-03-23`, retrieved 2026-10-26)
- Countries: Russia (ClinicalTrials.gov record NCT03088670, source copy `cardio:ctgov-nct03088670-2017-03-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03088670-2017-03-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients.
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Gosogliptin
- Intervention (Drug): Vildagliptin
- Intervention (Drug): Metformin
- Lead sponsor: SatRx LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: f77671f83cc202863e5d9c8fffa5e8ae7f659505d8928cc1417dd599a1cbd623
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
